Source BioScience and Oxford Gene Technology Collaborate to Deliver Next-Generation Sequencing Service
Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio.
Source BioScience announced that it has acquired the next-generation sequencing services business from Oxford Gene Technology (OGT) in a move to expand its products and services portfolio. The transfer of business from OGT to Source BioScience is hoped to contribute to the continued success and organic growth of the company.
Nick Ash, CEO of Source BioScience commented in a press statement that the company has forged a strong relationship with OGT and worked together on several projects. Ash said that with this acquisition, customers can now benefit from laboratory services from Source BioScience in conjunction with OGT’s analysis software.
According to Mike Evans, CEO of OGT, the company’s analysis software will be licensed to Source BioScience as part of the transfer, allowing customers continued access to the genetic analysis that OGT provides.
Source: Source BioScience
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
